



Paris, 14 February 2014, 5.45 pm

Quarterly information – Fourth quarter 2013

Turnover up 56% compared to 2012 Fourth quarter

€1,933 thousand year-to-date turnover as of 31 December 2013

€31.9 million cash reserves

Clinical development of Masitinib in 12 phase 3 studies

AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today reports its revenues for the fourth quarter of 2013 and provides an update on its activities for this period.

I. Fourth quarter sales of 2013

AB Science revenues amounted to €496 thousand in the fourth quarter 2013, vs. €317 thousand in the third quarter of 2012, up 56%. The company turnover amounts to €1,933 K€ as of 31 December 2013, as compared with €1,340 thousand one year earlier, which represents a growth of 44%.

These revenues derive from the commercial exploitation of masitinib in veterinary medicine in Europe and in the United States.

II. Update on financial situation as of 31 December 2013

AB Science cash¹ was €31.9 million as of 31 December 2013, vs. €23.4 million in 30 June 2013.

III. Key event of the third quarter of 2013

Masitinib is currently developed in 12 phase 3 indications (6 in oncology, 3 in inflammatory diseases, and 3 in neurodegenerative diseases) and 10 oncology indications in phase 2.

AREA	INDICATION	STUDY	STATUS
	GIST in first-line treatment	Phase 3	On-going
	GIST in second-line treatment	Phase 3 confirmatory	On-going
	Metastatic melanoma with JM mutation of c-KIT	Phase 3	On-going
	Relapsed metastatic colorectal cancer	Phase 3	On-going
Oncology / Hematology	Relapsed multiple myeloma	Phase 3	On-going
	Pancreatic cancer	Phase 3 confirmatory	To be initiated
	Relapsed metastatic non-small cell lung cancer	Phase 2	On-going
	Relapsed metastatic prostate cancer	Phase 2	On-going
	Relapsed metastatic triple negative breast cancer	Phase 2	On-going
	Relapsed metastatic non triple negative breast cancer	Phase 2	On-going

¹ Cash: available cash, cash equivalent and financial assets invested in certificates of deposit.

	Relapsed metastatic melanoma	Phase 2	On-going
	Relapsed metastatic liver cancer	Phase 2	On-going
	Relapsed metastatic gastric cancer	Phase 2	On-going
	Relapsed metastatic head and neck cancer	Phase 2	On-going
	Relapsed glioblastoma multiforme	Phase 2	On-going
	Relapsed peripheral T-cell lymphoma	Phase 2	On-going
Non Oncology	Indolent Systemic Mastocytosis	Phase 3	On-going
	Non controlled severe persistent asthma	Phase 3	On-going
	Refractory rheumatoid arthritis	Phase 3	On-going
	Alzheimer's disease	Phase 3	On-going
	Progressive forms of multiple sclerosis	Phase 3	On-going
	Amyotrophic Lateral Sclerosis	Phase 3	On-going

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signaling pathways within cells. Through these PKIs, the Company targets diseases with high unmet medical needs (cancer, inflammatory diseases, and central nervous system diseases), in both human and veterinary medicines.

AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine in Europe and in the USA, and is pursuing nine on-going phase 3 studies in human medicine in GIST in 1st and 2nd line of treatment, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, mastocytosis, severe persistent asthma, rheumatoid arthritis, Alzheimer disease and progressive multiple sclerosis. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

More information is available on our website: www.ab-science.com.

Disclaimer

This press release does not constitute an offer to sell or a solicitation of an offer to buy AB Science shares. If you wish to obtain more comprehensive information about AB Science, please refer to documents available on our website www.ab-science.com. This release may contain certain forward-looking statements. Although the Company believes that these statements are based upon reasonable assumptions at the date of publication of this document, they are inherently subject to risks and uncertainties which could cause actual results to differ from the present figures and those expressed or implied in these statements.

AB Science – Financial communication & Press relations
contact@ab-science.com